Pharmacological Profile of Huperzine A, a Novel Acetylcholinesterase Inhibitor from Chinese Herb
Xi Can Tang,Yi Fan Han
DOI: https://doi.org/10.1111/j.1527-3458.1999.tb00105.x
1999-01-01
CNS Drug Reviews
Abstract:CNS Drug ReviewsVolume 5, Issue 3 p. 281-300 Free Access Pharmacological Profile of Huperzine A, a Novel Acetylcholinesterase Inhibitor from Chinese Herb Xi Can Tang, Corresponding Author Xi Can Tang State Key Laboratory of Drug Research, Shanghai Institute of Material Medica, Chinese Academy of Sciences, China Life Science and Biotechnology Joint Laboratory of the Chinese Academy of Sciences and the Hong Kong University of Science and TechnologyDr. Xi Can Tang, State Key Laboratory of Drug Research, Shanghai Institute of Material Medica, Chinese Academy of Sciences, 294 Tai Yuan Road, Shanghai 200031, China. Fax: 21-64370269.Search for more papers by this authorYi Fan Han, Yi Fan Han State Key Laboratory of Drug Research, Shanghai Institute of Material Medica, Chinese Academy of Sciences, China Department of Biochemistry, Hong Kong University of Science and Technology, Hong Kong Life Science and Biotechnology Joint Laboratory of the Chinese Academy of Sciences and the Hong Kong University of Science and TechnologySearch for more papers by this author Xi Can Tang, Corresponding Author Xi Can Tang State Key Laboratory of Drug Research, Shanghai Institute of Material Medica, Chinese Academy of Sciences, China Life Science and Biotechnology Joint Laboratory of the Chinese Academy of Sciences and the Hong Kong University of Science and TechnologyDr. Xi Can Tang, State Key Laboratory of Drug Research, Shanghai Institute of Material Medica, Chinese Academy of Sciences, 294 Tai Yuan Road, Shanghai 200031, China. Fax: 21-64370269.Search for more papers by this authorYi Fan Han, Yi Fan Han State Key Laboratory of Drug Research, Shanghai Institute of Material Medica, Chinese Academy of Sciences, China Department of Biochemistry, Hong Kong University of Science and Technology, Hong Kong Life Science and Biotechnology Joint Laboratory of the Chinese Academy of Sciences and the Hong Kong University of Science and TechnologySearch for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3458.1999.tb00105.xCitations: 89AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Ashani Y, Peggins JO, III, Doctor BP. Mechanism of inhibition of cholinesterase by huperzine A. Biochem Biophys Res Comm 1992; 184: 7719–7726. 10.1016/0006-291X(92)90649-6 CASWeb of Science®Google Scholar 2 Bowen DM, Allen SJ, Benton JS, et al. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 1983; 41: 266–272. 10.1111/j.1471-4159.1983.tb11838.x CASPubMedWeb of Science®Google Scholar 3 Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport 1996; 8: 97–101. 10.1097/00001756-199612200-00020 CASPubMedWeb of Science®Google Scholar 4 Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharmacol Biochem Behav 1998; 60: 377–386. 10.1016/S0091-3057(97)00601-1 CASPubMedWeb of Science®Google Scholar 5 Cheng YS, Lu CZ, Ying ZL, Ni WY, Zhang CL, Sang GW. 128 Cases of myasthenia gravis treated with huperzine A. New Drugs Clin Remedies 1986; 5: 197–199. Google Scholar 6 Coyle JT, Price DL, Delong MR. Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 1983; 219: 1184–1190. 10.1126/science.6338589 CASPubMedWeb of Science®Google Scholar 7 Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 11: 1403. 10.1016/S0140-6736(76)91936-X Google Scholar 8 Decker MW, McGaugh TL. The role of interaction between cholinergic system and other neuromodulatory systems in learning and memory. Synapse 1991; 7: 151–168. 10.1002/syn.890070209 CASPubMedWeb of Science®Google Scholar 9 De Sarno P, Pomponi M, Giacobini E, Tang XC, Williams E. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res 1989; 14: 971–977. 10.1007/BF00965931 CASPubMedWeb of Science®Google Scholar 10 Ellman GL, Courtney KD, Andre V, Jr., Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–95. 10.1016/0006-2952(61)90145-9 CASPubMedWeb of Science®Google Scholar 11 Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523–2529. PubMedWeb of Science®Google Scholar 12 Giacobini E. The second generation of cholinesterase inhibitors: Pharmacological aspects. In: R Becker, E Giacobini, eds. Cholinergic Basis for Alzheimer's Therapy. Boston : Birkhäuser, 1991: 247–262. 10.1007/978-1-4899-6738-1_29 Google Scholar 13 Giacobini E. Cholinesterase inhibitors for Alzheimer's disease therapy: From tacrine to future applications. Neurochem Int 1998; 32: 413–419. 10.1016/S0197-0186(97)00124-1 CASPubMedWeb of Science®Google Scholar 14 Guan LC, Chen SS, Cui QG, Lu WH, Tang XC. The effect of huperzine A on behavior and EcoG in animals. Acta Psychol Sin 1991;(2): 404–411. Google Scholar 15 Guan LC, Chen SS, Lu WH, Tang XC. The effect of huperzine A on behavior and EcoG in animals. Acta Pharmacol Sin 1991; 12: 496–500. Google Scholar 16 Grunwald J, Raveh L, Doctor BP, Ashani Y. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 1994; 54: 991–997. 10.1016/0024-3205(94)00501-X CASPubMedWeb of Science®Google Scholar 17 Hallak M, Giacobini E. Physostigmine, tacrine and metrifonate: The effect of multiple doses on acetylcholine metabolism in rat brain. Neuropharmacology 1989; 28: 199–206. 10.1016/0028-3908(89)90093-2 CASPubMedWeb of Science®Google Scholar 18 Han YF, Tang XC. Preclinical and clinical progress with huperzine A: A novel acetylcholinesterase inhibitor. In: R Becker, E Giacobini, eds. Alzheimer Disease: From Molecular Biology to Therapy. Boston : Birkhäuser, 1996: 245–250. Google Scholar 19 Harel M, Schalk K, Ehret-Sabatier L, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc Natl Acad Sci USA 1993; 90: 9031–9035. 10.1073/pnas.90.19.9031 CASPubMedWeb of Science®Google Scholar 20 Hartvig P, Wiklund L, Aquilonius SM, Lindström B. Clinical pharmacokinetics of centrally acting cholinesterase inhibitors. In: R Becker, E Giacobini, eds. Cholinergic Basis for Alzheimer Therapy. Boston : Birkhäuser 1991: 68–73. 10.1007/978-1-4899-6738-1_8 Google Scholar 21 Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985–991. 10.1001/jama.1994.03510370037029 CASPubMedWeb of Science®Google Scholar 22 Kumar V. Introduction to cholinesterase inhibitors used in Alzheimer's disease therapy. In: E Giacobini, R Becker, eds. Alzheimer's Disease: Therapeutic Strategies. Boston : Birkhäuser, 1994: 99–102. Google Scholar 23 Lallement G, Veyret J, Masqueliez C, Aubriot S, Bukhart MF, Bauichon D. Efficacy of huperzine in preventing soman-induced seizures, neuropathological changes and lethality. Fundam Clin Pharmacol 1997; 11: 387–394. 10.1111/j.1472-8206.1997.tb00200.x CASPubMedWeb of Science®Google Scholar 24 Laganiere S, Corey J, Tang XC, Wülfert E, Hanin I. Acute and chronic studies with the anticholinesterase huperzine A: Effect on central nervous system cholinergic parameters. Neuropharmacology 1991; 30: 763–768. 10.1016/0028-3908(91)90184-D CASPubMedWeb of Science®Google Scholar 25 Lin JH, Hu GY, Tang XC. Facilitatory effect of huperzine A on mouse neuromuscular transmission in vitro. Acta Pharmacol Sin 1996; 17: 299–301. CASPubMedWeb of Science®Google Scholar 26 Lin JH, Hu GY, Tang XC. Comparison between huperzine A, tacrine, and E2020 on cholinergic transmission at mouse neuromuscular junction in vitro. Acta Pharmacol Sin 1997; 18: 6–10. CASPubMedWeb of Science®Google Scholar 27 Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 1994; 330: 613–622. 10.1056/NEJM199403033300907 CASPubMedWeb of Science®Google Scholar 28 Liu FG, Fang YS, Gao ZX, Zuo JD, Sou ML. Double-blind control treatment of huperzine-A and placebo in 28 patients with Alzheimer disease. Chin J Pharmacoepidemiol 1995; 4: 196–198. Google Scholar 29 Liu J, Zhang HY, Tang XC, Wang B, He XC, Bai DL. Effects of synthetic (−)-huperzine A on cholinesterase activities and mouse water maze performance. Acta Pharmacol Sin 1998; 19: 413–416. CASPubMedWeb of Science®Google Scholar 30 Liu JS, Zhu YL, Yu CM, et al. The structure of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can J Chem 1986; 64: 837–839. 10.1139/v86-137 CASWeb of Science®Google Scholar 31 Lu WH, Shou J, Tang XC. Improving effect of huperzine A on discrimination performance in aged rats and adult rats with experimental cognitive impairment. Acta Pharmacol Sin 1988; 9: 11–15. CASWeb of Science®Google Scholar 32 Mo N, Dun NJ, Karczmar AG. Facilitation and inhibition of nicotine transmission by eserine in the sympathetic ganglia of the rabbit. Neuropharmacology 1985; 24: 1093–1101. 10.1016/0028-3908(85)90197-2 CASPubMedWeb of Science®Google Scholar 33 Nordberg A, Nilsson L, Adem A, Hardy J, Winblad B. Effect of THA on acetylcholine release and cholinergic receptor in Alzheimer brains. In: E Giacobini, R Becker, eds. Current Research in Alzheimer Therapy. New York : Taylor and Francis, 1988: 247–258. Google Scholar 34 Pang YP, Kozikowski AP. Prediction of the bonding site of huperzine A in acetylcholinesterase by docking studies. J Computer Aided Mol Des 1994; 8: 669–681. 10.1007/BF00124014 CASPubMedWeb of Science®Google Scholar 35 Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnomalities with senile plaques and mental test scores. BMJ 1978; 2: 1457–1459. 10.1136/bmj.2.6150.1457 CASPubMedWeb of Science®Google Scholar 36 Qian BC, Wang M, Zhou ZF, Chen K, Zhou RR, Chen GS. Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol Sin 1995; 16: 396–398. CASPubMedWeb of Science®Google Scholar 37 Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (−)-huperzine A. Natural Struct Biol 1997; 4: 57–63. 10.1038/nsb0197-57 CASPubMedWeb of Science®Google Scholar 38 Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136–145. 10.1212/WNL.50.1.136 CASPubMedWeb of Science®Google Scholar 39 Saxena A, Quan N, Kovach IM, et al. Identification of amino acid residues involved in the binding of huperzine A to cholinesterase. Protein Sci 1994; 3: 1770–1778. 10.1002/pro.5560031017 CASPubMedWeb of Science®Google Scholar 40 Skolnick AA. Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy. JAMA 1997; 277: 776. 10.1001/jama.277.10.776 PubMedWeb of Science®Google Scholar 41 Sun QQ, Xu SS, Pan JL, Guo HM, Cao WQ. Efficacy of huperzine A capsules on memory and learning performance in 34 pairs of matched junior middle school students. Acta Pharmacol Sin 1999; 20: 601–603. CASPubMedWeb of Science®Google Scholar 42 Sussman JL, Harel M, Frolow F, et al. Atomic structure of acetylcholinesterase from Torpedo californica: A prototypic acetylcholine-binding protein. Science 1991; 253: 872–879. 10.1126/science.1678899 CASPubMedWeb of Science®Google Scholar 43 Tang XC. Huperzine A (Shuangyiping): a promising drug for Alzheimer's disease. Acta Pharmacol Sin 1996; 17: 481–484. CASPubMedWeb of Science®Google Scholar 44 Tang XC, De Sarno P, Sugaya K, Giacobini E. Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat. J Neurosci Res 1989; 24: 276–285. 10.1002/jnr.490240220 CASPubMedWeb of Science®Google Scholar 45 Tang XC, Han YF, Chen XP, Zhu XD. Effects of huperzine A on learning and retrieval process of discrimination performance in rats. Acta Pharmacol Sin 1986; 7: 501–511. Google Scholar 46 Tang XC, Kindel GH, Kozikowski AP, Hanin I. Comparison of the effects of natural and synthetic huperzine A on rat brain cholinergic function in vitro and in vivo. J Enthnopharmacol 1994; 44: 147–155. 10.1016/0378-8741(94)01182-6 CASPubMedWeb of Science®Google Scholar 47 Tang XC, Xiong ZQ, Qian BC, Zhou ZF, Zhang CC. Cognitive improvement by oral huperzine A: A novel acetylcholinesterase inhibitor. In: E Giacobini, R Becker, eds. Alzheimer Therapy: Therapeutic Strategies. Boston : Birkhäuser 1994: 113–119. 10.1007/978-1-4615-8149-9_20 Web of Science®Google Scholar 48 Ved HS, Koenig ML, Dave JR, Doctor BP. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport 1997; 8: 963–968. 10.1097/00001756-199703030-00029 CASPubMedWeb of Science®Google Scholar 49 Wang H, Tang XC. Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Acta Pharmacol Sin 1998; 19: 27–30. CASPubMedGoogle Scholar 50 Wang MY. Enhancement and depression of cholinergic transmission by 9-amino-1,2,3,4-tetrahydroacridine in rat superior cervical ganglia. Chin Pharmacol Bull 1993; 9: 298–300. CASGoogle Scholar 51 Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (−)-huperzine A: Comparison with E2020 and tacrine. Eur J Pharmacol 1998; 349: 137–142. 10.1016/S0014-2999(98)00199-X CASPubMedWeb of Science®Google Scholar 52 Wang XD, Zhang JM, Yang HH, Hu GY. Modulation of NMDA receptor by huperzine A in rat cerebral cortex. Acta Pharmacol Sin 1999; 20: 31–35. Google Scholar 53 Wang YE, Feng J, Lu WH, Tang XC. Pharmacokinetics of huperzine A in rats and mice. Acta Pharmacol Sin 1988; 9: 193–196. CASPubMedWeb of Science®Google Scholar 54 Wang YE, Yue DX, Tang XC. Anticholinesterase activity of huperzine A. Acta Pharmacol Sin 1986; 7: 110–113. CASWeb of Science®Google Scholar 55 Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982; 215: 1237–1239. 10.1126/science.7058341 CASPubMedWeb of Science®Google Scholar 56 Xiong ZQ, Cheng DH, Tang XC. Effects of huperzine A on nucleus basalis magnocellularis lesion-induced spatial working memory deficit. Acta Pharmacol Sin 1998; 19: 128–132. CASPubMedWeb of Science®Google Scholar 57 Xiong ZQ, Han YF, Tang XC. Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuroreport 1995; 6: 2221–2224. 10.1097/00001756-199511000-00029 PubMedWeb of Science®Google Scholar 58 Xiong ZQ, Tang XC. Effects of huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats. Pharmacol Biochem Behav 1995; 51: 415–419. 10.1016/0091-3057(94)00416-G CASPubMedWeb of Science®Google Scholar 59 Xu SS, Cai ZY, Qu ZW, et al. Huperzine-A in capsules and tablets for treating patients with Alzheimer's disease. Acta Pharmacol Sin 1999; 20: 486–490. CASPubMedWeb of Science®Google Scholar 60 Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition and behavior in Alzheimer's disease. Acta Pharmacol Sin 1995; 16: 391–395. CASPubMedWeb of Science®Google Scholar 61 Xu SS, Xie HB, Du ZW, et al. Efficacy of tablet huperzine-A on memory and cognition in patients with benign senescent forgetfulness. Chin J Clin Pharmacol Ther 1997; 2: 1–4. Google Scholar 62 Yan XF, Lu WH, Lou WJ, Tang XC. Effects of huperzine A and B on skeletal muscle and electroencephalogram. Acta Pharmacol Sin 1987; 8: 117–123. CASPubMedWeb of Science®Google Scholar 63 Ye JW, Cai JX, Wang LM, Tang XC. Improving effects of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther 1999; 288: 814–819. CASPubMedWeb of Science®Google Scholar 64 Zhang CL. Therapeutic effects of huperzine A on the aged with memory impairment. New Drugs Clin Remedies 1986; 5: 260–262. Web of Science®Google Scholar 65 Zhang CL, Wang GZ. Effects of huperzine A tablet on memory. New Drugs Clin Remedies 1990; 9: 339–341. Web of Science®Google Scholar 66 Zhang GB, Wang MY, Zheng JQ, Tang XC. Facilitation of cholinergic transmission by huperzine A in toad paravertebral ganglia in vitro. Acta Pharmacol Sin 1994; 15: 158–161. CASPubMedWeb of Science®Google Scholar 67 Zhang RW, Tang XC, Han YY, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders. Acta Pharmacol Sin 1991; 12: 250–252. PubMedWeb of Science®Google Scholar 68 Zhu XD, Giacobini E. Second generation cholinesterase inhibitors: Effect of (L)-huperzine A on cortical biogenic amines. J Neurosci Res 1995; 41: 828–835. 10.1002/jnr.490410613 CASPubMedWeb of Science®Google Scholar 69 Zhu XD, Tang XC. Facilitatory effects of huperzine A and B on learning and memory of spatial discrimination in mice. Acta Pharmaceutica Sin 1987; 22: 812–817. CASPubMedGoogle Scholar 70 Zhu XD, Tang XC. Improvement of impaired memory in mice by huperzine A and huperzine B. Acta Pharmacol Sin 1988; 9: 492–497. CASPubMedWeb of Science®Google Scholar Citing Literature Volume5, Issue3September 1999Pages 281-300 ReferencesRelatedInformation